19 Dec 2016

Transparency notification

Read More
19 Dec 2016

UCB and Amgen announce submission of application for investigational osteoporosis medication romosozumab in Japan

Read More
19 Dec 2016

UCB’s anti-epileptic drug VIMPAT® (lacosamide) approved as monotherapy by European Commission

Read More
15 Dec 2016

Transparency notification

Read More
14 Dec 2016

New appointments on UCB's Board of Directors

Read More
7 Dec 2016

Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Read More
7 Dec 2016

Transparency notifications

Read More
2 Dec 2016

UCB highlights epilepsy research at the 2016 American Epilepsy Society Annual Meeting

Read More
2 Dec 2016

Transparency notification

Read More
17 Nov 2016

Transparency notification

Read More
Subscribe to